2022
Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI.
Borde T, Nezami N, Laage Gaupp F, Savic LJ, Taddei T, Jaffe A, Strazzabosco M, Lin M, Duran R, Georgiades C, Hong K, Chapiro J. Optimization of the BCLC Staging System for Locoregional Therapy for Hepatocellular Carcinoma by Using Quantitative Tumor Burden Imaging Biomarkers at MRI. Radiology 2022, 304: 228-237. PMID: 35412368, PMCID: PMC9270683, DOI: 10.1148/radiol.212426.Peer-Reviewed Original ResearchConceptsMedian overall survivalAdvanced-stage hepatocellular carcinomaTransarterial chemoembolizationHepatocellular carcinomaBCLC BBCLC COverall survivalTumor burdenBarcelona Clinic Liver Cancer (BCLC) staging systemLiver Cancer staging systemCancer (AJCC) staging systemConventional transarterial chemoembolizationDrug-eluting beadsAllocation of patientsContrast-enhanced MRIBackground PatientsSurvival benefitRetrospective studyStaging systemC tumorsTumor volumePatientsHeterogeneous patientsMonthsChemoembolization
2021
Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma
Saffo S, Peng C, Salem R, Taddei T, Nagar A. Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. Digestive Diseases And Sciences 2021, 67: 1409-1416. PMID: 33811566, PMCID: PMC8487432, DOI: 10.1007/s10620-021-06967-7.Peer-Reviewed Original ResearchConceptsNeoadjuvant chemotherapyBiliary drainageDuctal adenocarcinomaSingle-center cohort studyHigh-volume tertiary centerPancreatic head ductal adenocarcinomaBackgroundPancreatic ductal adenocarcinomaUse of chemotherapyMultidisciplinary treatment modelCancer-related deathImplementation of guidelinesDelivery of careElectronic medical recordsResectable diseaseCohort studySurgical complicationsSurvival benefitTertiary centerPostprocedure complicationsPreoperative jaundiceAppropriate indicationsMedical recordsTherapeutic endoscopistsOutcome dataPractice trends
2020
Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma.
Kanneganti M, Mahmud N, Kaplan DE, Taddei TH, Goldberg DS. Survival Benefit of Liver Transplantation for Hepatocellular Carcinoma. Transplantation 2020, 104: 104-112. PMID: 31283688, PMCID: PMC6928443, DOI: 10.1097/tp.0000000000002816.Peer-Reviewed Original ResearchConceptsIncremental survival benefitLiver transplantSurvival benefitHepatocellular carcinomaEnd-stage liver disease (MELD) scoreOverall long-term survivalIntermediate-stage hepatocellular carcinomaLiver Disease scoreRetrospective cohort studyStage hepatocellular carcinomaHazard of deathVeterans Health AdministrationImmortal time biasLong-term survivalUnderwent resectionLiver transplantationAnalytic cohortCohort studyCurative optionMultivariable modelHCC diagnosisDisease scoreResectionPatientsHealth Administration
2018
Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls
Costantino A, Taddei T. Primary Liver Tumors Other than Hepatocellular Carcinoma: Clinical and Molecular Pearls. Current Hepatology Reports 2018, 17: 412-424. DOI: 10.1007/s11901-018-0426-6.Peer-Reviewed Original ResearchHepatocellular carcinomaRare tumorRare liver tumorGreater survival benefitRare malignant tumorRecent FindingsRecent literatureMetastatic diseaseSurgical resectionSurvival benefitAtypical presentationTherapeutic optionsPrimary liverNovel therapiesDifferential diagnosisMalignant tumorsFibrolamellar HCCLiver tumorsTherapeutic interventionsTumor typesTumor biologyCarcinomaTherapeutic possibilitiesTumorsMolecular pathwaysOngoing studiesThe effect of socioeconomic factors on the outcome of hepatocellular carcinoma.
Sellers C, Ludwig J, Uhlig J, Stein S, Taddei T, Kim H. The effect of socioeconomic factors on the outcome of hepatocellular carcinoma. Journal Of Clinical Oncology 2018, 36: 466-466. DOI: 10.1200/jco.2018.36.4_suppl.466.Peer-Reviewed Original ResearchMedian overall survivalCancer-directed treatmentOverall survivalHepatocellular carcinomaPrivate insurancePrimary insuranceInner-city tertiary care hospitalDecreased median overall survivalCox proportional hazard modelingMultivariate Cox proportional analysisCox proportional analysisTertiary care hospitalOS of patientsKaplan-Meier curvesProportional hazard modelingSocioeconomic factorsMedian OSSurvival benefitCare hospitalConsecutive patientsAJCC stageCancer RegistryMean ageTreatment courseSurvival advantageSorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchConceptsAdvanced hepatocellular carcinomaHepatocellular carcinomaOverall survivalBarcelona Clinic Liver Cancer (BCLC) systemManagement of HCCVeterans Health Administration hospitalsRetrospective cohort studyFirst-line therapySimilar survival outcomesChild-TurcottePugh scoreComorbidity indexChart abstractionCohort studySurvival benefitSystemic therapyBCLC stagePrimary outcomePrescriber typeSurvival outcomesAdministration HospitalMultivariable modelProvider specialtyCancer stagingHCC diagnosis